60 results
Page 2 of 3
8-K
EX-99.1
kzm7whujf
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
8-K
EX-99.1
g8w9p
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
9m0cj565trncy
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
EX-99.1
vp3uea6 i1xpg16f
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
ujvpb6nxif 9jv80ei
22 Dec 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
331n9dhngn1
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
8-K
EX-99.1
g622nf
5 May 21
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
7:52am
8-K
EX-99.1
ppx0bxsl
27 Aug 20
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million
6:02am
8-K
EX-99.1
mr0rpahetq 9qpnkjsvb
27 Aug 20
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering
12:00am
8-K
EX-99.1
opd hfo0du
13 Mar 20
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
4:44pm
8-K
EX-99.1
o79j444w
4 Mar 20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
5:09pm